– June 1, 2004
June 1, 2004
View Issues
-
Gefitinib as a Last Treatment Option for Non-Small Lung Cancer: Durable Disease Control in a Subset of Patients
Gefitinibs single-agent activity in a group consisting of pretreated NSCLC patients is confirmed. Side-effects of gefitinib were mild. Prolonged survival was associated with good PS and less significantly with a never-smoking history, female gender and histology. Additional studies on mechanisms of tumor control and selection of target populations for this remarkable new drug are warranted. -
Cancer Screening for Older Women: The Importance of Health Status
Cancer screening for older women remains an area of active investigation. One current recommendation is to perform screening for individuals with a life expectancy of 5 years or more, as early detection of tumor in these individuals is more likely to have an impact on survival. In this cross-sectional population based study from California, it is apparent that screening is currently applied to older women without consideration of health status. Thus, for many, mammography and Pap smears are being obtained with little hope of benefit. -
Lower-Dose Chemo for SCLC: Comparable Results in Low PS Patients
In a phase II trial, the combination of low-dose carboplatin and paclitaxel was shown to be well tolerated by elderly and, or frail (ECOG performance status 2) patients with advanced small cell lung cancer. Response rates and survival were comparable to those published for other combinations. -
Adjuvant Radiation Determined for Intermediate Risk Endometrial Cancer! Or has it?
The strength of a clinicians recommendation for patient care is greatest in data generated through carefully conducted experimental studies. In many cases, this quality of data is generated from randomized clinical trials where a novel intervention is compared against some standard of care. When properly designed and conducted, positive or negative results will generally provide convincing evidence to support a change in that standard or refute one, particularly if the outcomes are independently confirmed. -
Pharmacology Watch: Missing Link Between Vaccines and Diabetes
Breast Cancer and the Use of Statins; Warnings Issued for IBS Drugs; FDA Actions -
Clinical Briefs in Primary Care Supplement
-
Readers are Invited